FDA issues complete response to Daiichi Sankyo-MSD’s BLA for NSCLC

2024-06-27

交易

临床结果免疫疗法临床2期上市批准并购

FDA issues complete response to Daiichi Sankyo-MSD’s BLA for NSCLC

Preview

来源: Pharmaceutical Technology

The safety profile of the product in the Phase II trial was consistent with previous trials in NSCLC. Credit: Jo Panuwat D/ Shutterstock.

The US Food and Drug Administration (FDA) has provided a complete response letter for Daiichi Sankyo and MSD’s biologics licence application (BLA) seeking approval for patritumab deruxtecan (HER3-DXd) to treat non-small cell lung cancer (NSCLC).

The BLA sought accelerated approval for the antibody-drug conjugate for adults with locally advanced or metastatic EGFR [epidermal growth factor receptor]-mutated NSCLC previously treated with two or more systemic therapies.

The regulator highlighted inspection findings at a third-party manufacturing facility.

The letter did not query the submitted efficacy or safety data for patritumab deruxtecan.

Daiichi Sankyo research and development global head Ken Takeshita stated: “We will work closely with the FDA and the third-party manufacturer to address the feedback as quickly as possible in order to bring the first HER3-directed medicine to patients with previously-treated EGFR-mutated non-small cell lung cancer.

See Also:Verona scores FDA approval for Ohtuvayre as COPD maintenance therapy

Preview

来源: Pharmaceutical Technology

FDA go-ahead for Verona Ohtuvayre transforms US COPD exacerbator market

Preview

来源: Pharmaceutical Technology

“We remain confident in the ability to develop this medicine to its full potential.”

The BLA was based on initial results from the multicentre, global, open-label, two-arm Phase II HERTHENA-Lung01 clinical trial which assessed the drug’s safety and efficacy in 225 patients.

The study demonstrated an objective response rate of 29.8%, including one complete response and 66 partial responses, with a median duration of response of 6.4 months.

The safety profile of patritumab deruxtecan was consistent with previous Phase I trials in NSCLC.

Thrombocytopenia, neutropenia, anaemia, leukopenia, fatigue, hypokalemia and asthenia were the most common severe treatment-emergent adverse events observed in the trial.

Merck Research Laboratories global clinical development oncology head and senior vice-president Marjorie Green stated: “Patients with previously treated EGFR-mutated non-small cell lung cancer often experience recurrence and have limited treatment options.

“We are committed to working with Daichi Sankyo and the FDA to prioritise making patritumab deruxtecan available to these patients in need.”

In January 2024, MSD signed a definitive agreement to acquire Harpoon Therapeutics for $680m, strengthening its immunotherapy portfolio for cancer treatment.

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构